



Companies presenting at Summit

	Liaison	Date/Time (ET)	Deal Status
Acivilate, Inc.	David Nethero	4/26 at 4 pm	
Alice	Gwen Edwards	4/26 at 4 pm	Open round
Beckon	Carolyn Fikke	4/26 at 3:15 pm	
CabinetM	Jo Ann Corkran	4/28 at 2:15 pm	Open round
Cadenza Innovation	Doug Bateson	4/26 at 4:45 pm	Open round
Chromis Fiberoptics, Inc.	Lynn Baine	4/26 at 3:15 pm	
CNote	Gwen Edwards	4/27 at 2:15 pm	
Concerto Biosciences, Inc.	Laura Davis	4/28 at 4:45 pm	
Day Zero Diagnostics	Deb Kemper	4/27 at 4 pm	Open round
otto (fka Dev/Con Detect)	Mary McCaffrey	4/27 at 2:15 pm	
Diesel Labs	Sheila Narayan	4/28 at 4 pm	Open round
Forte	Deb Kemper	4/28 at 4 pm	Open round
Govenda by BoardBookit	Catherine Abbott	4/27 at 2:15 pm	
Groupize	Gail Hoffman	4/27 at 4 pm	Open round
Hilltop Biosciences, Inc.	Laura Davis	4/27 at 3 pm	Open round
Hohm, Inc	Deborah Doyle	4/28 at 3 pm	
Joylux, Inc	Deborah Doyle	4/27 at 4:45 pm	Open round
Kalion, Inc.	Joan Zief	4/26 at 4 pm	Open round
Lark	Gwen Edwards	4/28 at 5:30 pm	
Little Passports	Jo Ann Corkran	4/28 at 4:45 pm	
Nalu Bio, Inc.	Carolyn Fikke	4/27 at 4 pm	Open round
Nanodropper, Inc.	Kathy Lynn-Cullotta	4/26 at 4 pm	
NopSec	Deb Kemper	4/28 at 2:15 pm	Open round
NX Prenatal Inc	Laura Baldwin	4/27 at 3 pm	
Ocologica Inc	Kathryn Swintek	4/27 at 5:30 pm	Fall 2021
Onboard Dynamics Inc.	Linda Laskowski	4/26 at 3:15 pm	Open round
Open Road	Kathryn Swintek	4/28 at 3 pm	
OtoNexus Medical Tech	Gwen Edwards	4/28 at 2:15 pm	
Physician 360	Susan Nethero	4/27 at 2:15 pm	
Pomp & Whimsy, Inc.	Eric Nadler	4/27 at 4:45 pm	
Roar/Perform Live	Janet DeFrino	4/28 at 3 pm	
Sara Happ	Carolyn Fikke	4/28 at 4 pm	Open round
Shareablee	Emily Susskind	4/27 at 4 pm	
Sports Innovation Labs	Sheila Narayan	4/27 at 3pm	Open round
Tempo Automation	Gwen Edwards and Jo Ann Corkran	4/27 at 3 pm	
Terecircuits Corporation	Iris Fujiura	4/28 at 4:45 pm	
Work Truck Solutions	Jo Ann Corkran	4/27 at 4:45 pm	
Zenflow	Jo Ann Corkran	4/26 at 3:15 pm	

Acivilate. No open funding round.

Acivilate's Pokket is a SaaS enterprise platform that enables justice agencies and human services providers to work together to cut the number of people going back to prison or jail. The company engages with the returning citizen in their own rehabilitation and lets them share their treatment plan information. Acivilate has the potential to collect the first broad, cross-silo database on human services in the US, to help guide policy.

Covid has presented obstacles to the rollout of Pokket, with several agencies holding off on new contract negotiations. However, the company has continued to work several opportunities including a launch with a healthcare partner in Georgia, Arizona Corrections feeding people into the Medicaid and Medicare payment model, a pilot with community groups in Maryland and Florida, and Louisiana requesting a proposal to take Pokket statewide for a subset of their parole population - a huge win.

Golden Seed first funded Acivilate in 2018 in a Series Seed round with a \$4.38m pre-money valuation, and has since followed up with additional funding in the form of a convertible note with an \$8 million cap which will convert into the Series A. The total amount invested by Golden Seeds members is \$227,500.

Louise Wasilewski is the CEO / Co-Founder. She founded Acivilate based on her family's experience with the criminal justice system, leading her to be intensely devoted to the idea behind the product. Louise has a broad background in the science and tech space, ranging from being a rocket scientist to consulting to leading the tech division at Cox. She has experience in four startups and holds four patents. She started Acivilate to create second chances for families like hers and will speak with Golden Seeds members about promising future developments for the company.

Hello Alice - Open Round.

Hello Alice is the first free digital platform that makes smart, instant connections between business owners and the resources they need to accelerate sustainable growth. Hello Alice is open to all founders and utilizes machine learning to prioritize access for the New Majority - women, minorities, veterans, and other underrepresented business owners, by matching them to personalized opportunities and resources.

Launched in 2017, the company achieved product scale in late 2018. Hello Alice directly engages 375,000 small business owners each week on their platform and have doubled enterprise sales each year through their SaaS offering. Unique to Hello Alice, they also offer support to all of the business networks, such as Chambers of Commerce, Accelerators and membership groups such as the NAACP. 65% of the Hello Alice platform are women business owners.

Their mission remains to emerge as the number one platform to help small business owners grow and come out of the pandemic stronger than ever. Critical to this vision - they are heading towards becoming the number one source of capital to SMBs through credit, lending and grants.

Golden Seeds was first introduced to Alice through our Silicon Valley chapter in June 2018. In late 2019, Golden Seed members invested \$266,500 in the company's Series A round which was led by Silicon Valley Bank and in which the company raised \$7million at \$25 million pre-money. The company is currently raising an additional \$15 million through a Series B round led

by QED Fund VI at \$76 million pre-money. Founders Elizabeth Gore and Carolyn Rodz will speak to Golden Seeds members about the strides Hello Alice has made since our initial investment and speak to the current raise.

Please note that while prorata elections are due on Monday, April 26, Elizabeth and Carolyn have offered to extend this deadline to Wednesday, April 28th to allow members who may be new to Hello Alice to have an opportunity to learn more about their plans for the future. Additional information on the raise will be available through the deal room ahead of the session.

Beckon Foods. No open funding round.

Beckon makes the first premium line of lactose-free, dairy ice cream, with a focus on meeting customer priorities of taste and texture. The product, which benefits from a US utility patent, contains no gums, stabilizers or additives, and uses only clean ingredients, is offered in over 1600 retail locations, including nationwide distribution in Whole Foods and Sprouts, as well as via the company's website. Their products uniquely serve the over 25% of the population, and 65%-90% of the African American, Latin and Asian population, that are lactose-intolerant. The company is poised to expand their business through added retailers, and an expanded product offering, and is focused on achieving profitability in 2022, with projected revenues of \$35 million by 2025.

Beckon was first introduced to Golden Seeds through Robin Hood Ventures, lead on the company's Series Seed round, which sought to raise \$2 million on an \$8.2 million pre-money valuation. Golden Seeds members, through GS Beckon Ice Cream LLC, invested \$265,000 in the Series Seed in January 2021. In 1Q 2021, the company closed the Series Seed round, which was oversubscribed. The company is now looking towards an early 2022 Series A offering.

Co-Founders Gwen Burlingame and Kathryn Flannery will join us to discuss 2020 results and plans for the future.

CabinetM – Open funding round.

CabinetM is a Marketing Technology Management platform that large enterprises use to track and manage the spend and performance of the technology they use to acquire, engage and retain customers, and create the customer experience. CabinetM customers include well-known brands: Major League Baseball, William-Sonoma, LogMeIn, Janus Henderson Investors, and others. According to Gartner, marketing technology represents between 26 and 29% of the marketing budget. Yet, most organizations do not have a way to centralize oversight and performance management and struggle with the problems of duplicate contracts, overlapping technologies, and non-performing technologies. Organizations using CabinetM typically reduce technology spend by 20% within 6-12 months and can produce reports and visualizations in minutes rather than hours or days.

In total, excluding the original working capital contributed by the founders, CabinetM has raised \$1,515,541 in two notes, of which \$897,000 has come from Golden Seeds investors. Both notes convert at a 20% discount.

The company is raising a formal Seed Round in order to scale the company through a SAFE.

Sheryl Schultz and Anita Brearton are co-founders of CabinetM. They are also Golden Seeds members, and were the originators of Open Office Hours, now used throughout Golden Seeds to meet new entrepreneurs. They will review results from 2020 and discuss plans for the future.

Cadenza Innovation – Open funding round

Cadenza Innovation's breakthrough design for a lithium-ion battery with compelling advantages in safety, energy density and manufacturing cost will allow a significant capture of a rapidly expanding multi-billion dollar industry. This novel design approach supports applications in the electric vehicle, energy storage and other specialty markets. Cadenza's technology has been tested by multiple third-party entities, has received all necessary Underwriters Laboratories (UL) certifications, and is supported by a robust internationally accepted patent portfolio. Cadenza has successfully demonstrated the supercell technology in a Fiat 500e, and in late 2020 the New York Power Authority (NYPA) began a trial of an energy storage system using lithium-ion batteries using Cadenza Innovation's 'supercell' architecture. The global market for energy storage, in which the demand for lithium-ion batteries is expected to dominate, is projected to grow to over \$500BN by 2035, and Cadenza is poised to benefit significantly from this growth.

Golden Seeds was first introduced to Cadenza Innovation in 2016. Golden Seeds led the company's Series A round, an \$11 million raise with a \$70 million pre-money valuation. In 2018, the company raised a follow-on Series A-1, raising an additional \$9 million at a pre-money valuation of \$123 million. Cadenza has now scheduled the final close on their Series B round, raising an additional \$5 million at a \$65 million pre-money basis, for early May 2021. The Golden Seeds Fund and members, through an LLC, have invested more than \$7.3 million in the company and the technology, and in addition to being steadfast supporters to the company, are among the largest investors in Cadenza Innovation.

We will hear from Dr. Christina Lampe-Onnerud, CEO of Cadenza, and a corporate strategist with extensive C suite experience in building technology-based businesses from inception to rapid revenue growth. She is widely acknowledged in the global energy storage industry for innovative and technologically pioneering work, has been recognized twice by the World Economic Forum as a Technology Pioneer and is a lifetime member of the Royal Swedish Academy of Engineering Sciences. She is a highly analytical leader with a solid track record of attracting and growing high performance teams to develop technologies that deliver game changing solutions to global markets.

Chromis. No open funding round.

Chromis Technologies is disrupting the status quo in the amorphous fluoropolymers industry. The founding senior scientists of the company have over 100 years of collective experience, with advanced degrees from some of the world's leading universities and are the inventors and authors of dozens of patents and technical papers in their fields of expertise.

The company has built a scalable and extensible technology platform that allows them to modify the properties of their advanced materials and downstream products for specific use cases.

Chromis is using this capability to deliver solutions for a cleaner environment, to transmit data at the speed of light, and to enable new technologies and products across industries.

Golden Seeds members and funds have invested nearly \$2.4 million in Chromis since 2006, with an initial investment in the company's \$1 million Series A round, with a fully diluted pre-money valuation of \$5.4 million and continuing through the most recent raise in the Series B with an \$18 million pre-money valuation.

Frank Graziano is the CEO of Chromis, and he began his career as an investment banker, helping to build project finance, derivatives, structured finance, and various strategic advisory practices at Bank of America and Nikko Securities. As a deal maker and operating executive for merchant banking firm Recca & Company, he acquired, restructured, and turned around portfolio companies. Frank assisted with the IPO of Mail.com and served as its Senior Vice President of Strategy & Corporate Development, completing over a dozen global acquisitions and strategic investments as the company grew revenues from \$1 million to \$120 million in two years. He then served as Chief Marketing Officer for its successor, cloud services company EasyLink Services (now part of OpenText). He was subsequently recruited by the founder and CEO of Comodo (acquired by Francisco Partners), joining the world's largest digital certificate authority as its Chief Revenue Officer.

Frank, who will speak to Golden Seeds members at Summit, joined the team at Chromis Technologies after becoming familiar with the company and its founding scientists while he was a member of Golden Seeds.

CNote. No Open Funding Round

CNote is a women-led impact investment platform that uses technology to unlock diversified and proven community investments to generate economic mobility and increase financial inclusion. Every dollar invested on CNote's platform funds small businesses owned by women and people of color, affordable housing, and economic development in financially underserved communities across America. With the mission of closing the wealth gap, CNote's customizable products allow anyone to generate social and economic returns by investing in the causes and communities they care about.

CNote was first introduced to Golden Seeds through our Silicon Valley chapter in February 2019. Members initially invested in a Convertible Note with an \$10 mm cap which in 2020 converted into the \$3 million Series Seed round led by Manchester Story with a \$15 million post-money valuation. To date, Golden Seeds members have invested over \$500,000 in CNote.

Cat Berman, CNote's CEO and co-Founder, is a three-time entrepreneur who has built scaled multimillion-dollar businesses. She is joining us to discuss both milestones met, and challenges faced in 2020, and will provide insight into plans for 2021 and beyond.

Concerto Biosciences. No open funding round.

Our understanding of the importance of the microbiome in health and disease has exploded in the past ten years. Concerto Biosciences is introducing a systematic, high-throughput approach to identifying the exact components of our microbiome that can prevent disease and promote health. Using a patented screening platform, the company discovers microbial ensembles, combinations of microbes that heal people, plants, and the planet. Their first products will treat skin disorders like eczema, allowing hundreds of millions of people globally to enjoy life free from inflamed, itchy skin.

They anticipate that they will generate revenue through co-development partnerships, revenue and royalties from product sales, and out-licensing agreements. Their initial product, Ensemble No.2, will solve an unmet market need for treating eczema with a unique approach, allowing the company to price the product at a premium relative to existing, less effective solutions. Concerto's other products will follow similar pathways, ensuring profit maximization.

Golden Seeds was first introduced to Concerto last summer through our Boston chapter. In the fall, members and the Golden Seeds Venture Fund invested a total of \$125,000 in a \$1M pre-seed financing round with a \$7.5M cap. The round, led by 8VC, was oversubscribed, with Concerto and 8VC, expanding the round for Golden Seeds participation.

The management team is led by a strong and well-connected team of experienced scientists and engineers. Dr. Cheri Ackerman, a co-founder and CEO, will join us to discuss Concerto's systematic approach to solving high-impact challenges in human health, food production and bioremediation.

Day Zero Diagnostics. Open funding round.

The growth of antibiotic resistance is creating a public health crisis. In a severe infection like sepsis, patients can die within hours, but current diagnostics for antibiotic resistance can take 2-5 days or never return a result at all. Physicians are left to treat using trial and error approaches based on limited information – the exact opposite of precision medicine.

Day Zero Diagnostics is developing rapid, whole genome sequencing-based diagnostics to modernize infectious disease diagnosis and treatment. These technologies can provide the species ID and antibiotic resistance profile of a bacterial infection within hours, rather than days, so that patients can be treated with the most effective antibiotic quickly. Faster treatment with the right antibiotic saves lives and reduces the cost and complications associated with extended episodes of care.

Day Zero is also developing technologies to help control HAIs (healthcare-associated infections), where antibiotic resistant organisms can be especially dangerous. The company's rapid turnaround epiXact service uses whole genome sequencing to provide infection control professionals with precise information on pathogen relatedness quickly, so they can make the right intervention decisions with confidence.

Golden Seeds was first introduced to Day Zero in 2016. In early 2017, members invested \$297,500 in the company's Series Seed, a \$3mm round led by Golden Seeds. The Series Seed had a pre-money valuation of \$6.5mm. Golden Seeds members and the Golden Seeds Venture Fund invested an additional \$265,000 in Day Zero's \$8.5mm Series A round in 2018, led by Triventures III Fund with a pre-money valuation of \$18mm. The round was oversubscribed.

Jong Lee, CEO of Day Zero, will join us for to discuss Day Zero's progress to date, and plans for the future.

otto (formerly known as DevCon). No open funding round.

Otto is making the internet safer and security easier through a next-generation runtime application security software. They save companies time and money while reducing risk and mitigating threats that can cost hundreds of millions in data breaches.

The company has Integrations with some of the largest CDNs, Cloud marketplaces and CMSs which allows teams to start securing their company in seconds with no-code and low-code setup. Otto is committed to protecting consumers from cyber threats by democratizing cyber security (i.e., making it free for consumers).

Golden Seeds members first invested in the company's \$4.5 million Series Seed with a \$12 million pre-money valuation led by Las Olas and followed up with investment in a \$2 million Series Seed 3 with an \$18 million pre-money valuation, again led by Las Olas. In total, members have invested \$419,000.

Maggie Louie, CEO, and Casey Hester, COO, co-founders of otto, bring proven experience to the company as digital leaders, and will speak with members about challenges and significant milestones for the company and the industry.

Diesel Labs – Upcoming funding round

Despite volatility in many industries, media content consumption remains high. Diesel Labs is a content analytics company that illuminates audience preferences across the entire media spectrum. Using a sophisticated machine learning based approach, Diesel has developed decision tools for every step in the content lifecycle: ideation, development, distribution, and sales/marketing. All content - from movies and shows to short form video and even podcasts - is measured and organized by relevance. This quality-based approach surfaces new audience information and allows for strategic decisions to be made no matter the type, format, or source of content thereby driving better results for producers and advertisers alike.

Diesel Labs has a sophisticated product that provides unique analytics. It is currently being used by several major broadcast television networks and multiple leading streaming platforms (including a member of the FAANG cohort). The company estimates that the current market size of \$700mm is likely to double in the next 2-3 years. With this growth and the corresponding need for data to support content strategy and development, Diesel Labs will be well positioned to be a leading provider of analytics to the industry.

Golden Seeds was first introduced to Diesel Labs in November 2019, and Golden Seeds members invested \$240K in the company's \$1.7M Convertible Note through GS Diesel Labs LLC. The Note, with a \$8M cap and 20% discount on conversion, was led by Excelestar Ventures (a fund managed by Golden Seeds member Tasneem Dohadwala) which invested \$500K. In July 2020, in the height of the pandemic, Diesel Labs successfully closed their Note, hitting their fundraising target.

Anjali Midha will speak with members, addressing both milestones met and challenges faced in 2020, and will provide insight into plans for 2021.

Forte - Open funding round

FORTÉ automated hardware & software enable fitness studios to seamlessly live-broadcast their classes daily over FORTÉ's B2C subscription service or directly into the studio's website using FORTÉ's SaaS/White-Label premium digital offering. By leveraging FORTÉ's tech, studios can reach far beyond the 30 bodies that can physically attend their classes and consumers can have access to content from top studios. FORTÉ's proprietary and scalable technology enables studios to begin high quality live streaming of classes daily at a fraction of

the cost and implementation time of other solutions. The Covid-19 pandemic has only accelerated the adoption of these technologies because a digital offering is necessary to help stay in business until the pandemic is over. Almost every gym and fitness studio wants to have a digital platform in addition to their brick-and-mortar business to compete with Peloton and other on-line services.

Golden Seeds was introduced to Forte earlier this year. Members and Funds invested in a convertible Note led by 76 Capital with a \$17.5 million cap which will convert into a priced round at a 20% discount. In total, Golden Seeds invested \$412,500 in the Note.

Lauren Foundos will join us for the Summit to update and introduce members to the company. Lauren is the Founder and Chief Executive Officer, and spent a decade working on Wall Street.

Govenda by BoardBookit - No open funding round.

BoardBookit, a leader in board portal software, has recently announced that it has rebranded to Govenda. The new name and brand reflect the company's expanding vision and growing suite of corporate governance products. The product's evolution, from a board portal to a board relationship and compliance management platform, is the driving force behind the rebranding. The company's new name, logo, and suite of products address the rapidly changing needs of the corporate governance market.

In late 2020, the company completed a transaction with Growth Street Partners, who invested \$4 million directly into BoardBookit, and purchased \$3 million in shares from existing investors. With investors able to sell up to 53% of their shareholdings, while retaining the remaining shares in the company, this transaction resulted in 2.6x on shares sold for an estimated 1.4x of the capital invested, with the balance of shares remaining in the company through the LLC.

Golden Seeds first invested in BoardBookit in 2017 in a Series A round led by Golden Seeds with a pre-money valuation of \$3 million for a total of \$410,000.

Marion Lewis, who will speak to members at the Summit, is the Founder and CEO of BoardBookit. She is a results-driven entrepreneur with over 20 years of experience and success in the online world. She has provided the vision and leadership to bring this groundbreaking and powerful board management solution to market. Prior to founding BoardBookit, she was co-founder of Tachyon Solutions, a custom application development and interactive marketing firm, and served as its CEO for 21 years.

In addition to her professional accomplishments, Ms. Lewis has won a number of awards for her work and involvement in the entrepreneurial community, including the 1997 Susan B. Anthony Leadership Award and in 2005, she was named among the Best 50 Women in Business in Pennsylvania.

Groupize - Open funding round

Many of you know Groupize as the premier software solution for organizations to manage expense, travel and risk for meetings, events and guest travel. You may not know that Groupize is at an exciting inflection point as they have finalized a reselling arrangement with the largest expense management company SAP/Concur. Groupize has re-imagined meeting and event

management with easy to use, out of the box tools that simplify all processes for any size or type of event - virtual, hybrid and in-person.

As the entry point and centralized hub for corporations to manage expense, travel and risk for all meetings, projects and events, the benefits of the cloud-based solution include governing company costs through intelligent spend management, risk mitigation, duty of care, traveler safety, employee experience and productivity. With game-changing self-service capabilities, the award-winning technology delivers consistent enterprise workflows, allowing for compliant venue shopping and booking, attendee management, travel and logistics, reporting, budgeting and collaboration. As a result of the agreement, SAP/Concur's 1,800-member salesforce will begin to sell "SAP Event Management powered by Groupize" as an add-on to its existing platform serving this year. This reselling arrangement is a game changer for Groupize, and for their investors.

Golden Seeds was first introduced to Groupize in 2013 through our Boston chapter, leading the company's \$1.5 million Series A raise with a pre-money valuation of \$4.5 million. Over the years, members through an LLC, and the Golden Seeds Funds have continued to support the company with recent participation in the 2019 Seed round led by Thayer Ventures which raised \$2.5 million on a pre-money valuation of \$6 million, and earlier this year in a Convertible Note financing with a \$12 million cap which will convert into the next priced round at a 15% discount. \$275,000 remains available on the Note; the company has scheduled an additional close for mid-May. To date, Golden Seeds members and Funds have invested a total of \$3.6 million in the company.

Alisa de Gaspe Beaubien, Co-Founder and CEO of Groupize, will update members, and discuss plans for 2021.

Hilltop BioSciences, Inc. – Open funding round.

Hilltop BioSciences is an early-stage veterinary biotech company providing therapies to injured animals to regenerate and restore full functionality and long-term health. The company is producing a proprietary, easy-to-use, highly effective, room temperature, birth tissue-based allograft, a simple solution for effectively healing the body from injuries and several inflammatory diseases. The efficacy in this regenerative matrix is related to a full spectrum of growth factors, miRNA, peptides as well a healthy extracellular matrix, providing all of the sections of the regenerative orchestra needed for tissue regeneration. This therapy has been proven to generally improve the quality of healing, resulting in repairs with less scarring and thereby less chance of re-injury compared to other therapies (even stem cells).

Hilltop's strategy is to focus first on the US equine market (\$800M) with expectations of securing 15 to 25% of the market in 5 years. Success in this market will help bridge usage into the small animal market (~\$17B) and the international equine market (~\$7B).

Golden Seeds was first introduced to Hilltop BioSciences in 2019, and members invested \$100k in the Series Seed led by Launchpad, with a \$2.75 million pre-money valuation, on a direct basis. In 2020, the company raised a \$550k Bridge Note, and have recently opened a \$1.5 million Series A with a \$5.5 million pre-money valuation. Funds raised will be used for revenue generation using digital marketing and sales efforts, university-led studies in airway disease, further identifying new indications, and small animal (canine) R&D and early entry into the market.

Amanda Drobnis, CEO at Hilltop Biosciences, will update members on the company's progress to date, discuss use of funds, and plans for the future.

hOM – No funding round

Update for all members. hOM was the first boutique amenity manager for properties too "small" for traditional amenity management. They leverage technology to deliver amenity management and programming to all buildings, regardless of square footage, and at a fraction of the cost of competitors, or having buildings provide these services in-house.

hOM's services offer demonstrable value to landlords by helping satisfy the tenant experience, resulting in reduced unit turn-over costs and increased tenant generated word of mouth marketing. Their turn-key platform and customer service teams manage amenity packages from sign-up to maintenance, either building by building, or across multiple buildings managed by the same landlord.

hOM utilizes technology which can be integrated into building apps or offered independently to service, program, and sign-up tenants for events and classes. Typically, in a non-Covid-19 landscape, these events are held in the tenant's buildings' unstaffed gym, on unfinished rooftops, in lobbies or empty apartments to keep residents renting. In the current environment, hOM has demonstrated the flexibility of their business model by pivoting their amenity services by integrating a live-streaming platform for classes and events through white labelled sites.

Golden Seeds was first introduced to hOM in 2016, initially investing \$300,000 through the Golden Seeds Funds in the Series Seed with a pre-money of \$2.8mm. To date, Golden Seeds has invested a total of \$628,000 in hOM, including the most recent raise in a Convertible Note with a \$8mm cap.

Francesca will speak to Golden Seeds members about the sweeping changes made to adapt their business model to remain competitive during 2020, and future plans for the company.

Joylux – Open funding round.

Joylux is a consumer health-tech company reinventing the multibillion-dollar women's intimate health market with proprietary and patented home-use solutions for the millions of menopausal women suffering from pelvic floor issues. To date, Joylux has achieved more than \$4mm in sales and sold 20K devices. Using AI and telehealth partners, their patented, next gen connected device can help women monitor and manage their personalized care. Joylux was winner of the 2019 Angel Capital Association's Luis Villalobos Award for Most Innovative Company.

With limited marketing and sales spend, Joylux has driven double-digit growth rates and \$3.6M in total sales, with opportunities for continued growth with adequate capital funding. The anticipated growth strategy will reach \$100M+ in sales and profitability in the next 5 years.

Golden Seeds was first introduced to Joylux in 2016, and first invested in the Series Seed in December 2017 at a share price of \$0.2654. Members have invested in both the Series Seed and Series A round (\$0.3451/share) with total investment by Golden Seeds members of \$388,000 to date. To date the company has raised \$16 million. Joylux has opened a \$500,000

Convertible Note and is in discussions for their Series A-1 capital raise at an estimated \$38 million pre-money valuation.

Colette Courtion, CEO of Joylux, will discuss the company's solid performance in 2020 despite COVID closures, and plans to fuel growth and the company's continued potential to be a leading player in menopausal health.

Kalion. Open funding round.

Kalion is taking on the significant challenge of creating and commercializing innovative chemicals from biomass, developing important new molecules that can be derived in a greener manner and offer significant advantages over traditional oil-based molecules. They have harnessed the ability to use biological organisms (synthetic biology) to produce powerful chemical reactions allowing for a vastly superior purity of final products. Kalion has created a high purity glucaric acid that allows companies and researchers to fully exploit the unique properties of glucaric acid and related molecules. Glucaric acid has billion-dollar potential in multiple markets. Kalion is now ready to seize these markets via outsourced manufacturing for multiple customers.

Kalion has created a high purity glucaric acid that allows companies and researchers to fully exploit the unique properties of glucaric acid and related molecules. Low-cost, high purity glucaric acid enables products in a wide range of fields. Glucaric acid can be used to produce novel environmentally friendly high-performance water treatment solutions. It has also been shown to substantially increase the mechanical properties of certain classes of some textiles, polymers such as polyvinyl alcohol and at least four other classes of materials. Glucaric acid has also been incorporated in the manufacture of nylon via adipic acid as well as a future bio-friendly substitute for PET in two-liter bottles, FDCA. With its broad range of applications, glucaric acid has the potential to demonstrate that the use of bio-based materials will provide a wide range of benefits to the US economy.

Golden Seeds was first introduced to Kalion in 2013 and made the initial investment in the company's \$850,000 Series Seed with a pre-money valuation of \$1.7 million. Golden Seeds continued to support the company in the Series A, Series A-1, Series A-2 and most recently in 2019, as the company raised a \$3 million Series A-3, led by Golden Bench Capital, with a \$9 million pre-money valuation. To date, Golden Seeds members and Funds have invested a total of \$653,000 in Kalion, and their vision for developing new business from emerging technologies.

Darcy Prather, CEO will speak with members to review the company's progress to date, and to discuss the current Convertible Note financing round.

Lark. No open funding round.

Lark Health is a chronic disease prevention and management company that uses a cognitive behavioral therapy framework, conversational A.I., and connected devices to help people stay healthy and in control of their conditions. Lark's A.I. is continuously learning how to personalize the experience for the member and communicates via text-message-like interactions to monitor patients remotely, 24/7, while live nurses and health coaches are available when issues need to be escalated such as severe readings or medication changes. Lark's Diabetes Prevention Program, which is fully recognized by the CDC, Behavioral Health Program, Diabetes Care

Program, and Hypertension Program have served nearly 2 million members, and have demonstrated clinically validated outcomes. Lark works with many of the largest health plans and self-insured employers to help their members and employees live healthier lives.

Golden Seeds first invested in Lark with the Silicon Valley group, and a Boston member, in their first convertible note (post friends and family) in early 2010, then Golden Seeds participated significantly in the company's \$5 million Series A financing, led by Asset Management Company Centuries Fund at a \$8 million pre-money valuation. The company continued to grow, and Golden Seeds continued to support the growth investing over the years in the Series A-1, then Series A-2 (at a \$28 million pre-money valuation), then a \$10 million Series B raise (at a fully diluted pre-money valuation of \$70 million) and most recently in a \$40 million Series C offering led by King River Capital, with a pre-money valuation of \$170 million on a fully diluted basis. In total, Golden Seeds members and Funds have invested more than \$6.5 million in the company.

Julia Hu, CEO and Co-Founder of Lark, is a serial entrepreneur who was named to Business Insider's 30 Under 40 Changing Healthcare list and number one in "Top 10 Women in Tech to Watch" and "30 Under 30" by Inc. Magazine. Prior to founding Lark Health, Julia ran a global startup incubator, Clean Tech Open, her own green buildings startup, and was an entrepreneur in residence at Stanford's StartX. She dropped out of MIT's Sloan school to start Lark and has been driven ever since to make it a success.

Little Passports. No open funding round.

Little Passports' mission is to inspire children to discover the wonders of the world around them. The company creates innovative DTC content and toys for kids ages 3-12. Their current offerings include three geography subscriptions, two science-focused subscriptions, books, board games and science kits.

Little Passports has experienced consistently strong revenue growth, with 61% compound annual growth rate over the past 7 years. For their 2020 fiscal year, the company generated \$54MM in revenue, up 26% YoY. The demand for action-packed activity kits, delivered to the doorstep, has skyrocketed as families search for fun, innovative solutions to help their child's curious mind continue to thrive. With a customer retention rate of 94%, and exciting opportunities for product and channel expansion, Little Passports is on track to reach \$150mm in revenue by 2024.

Golden Seeds has had a long relationship with Little Passports. We were first introduced to Little Passports in 2010, with members and the Fund investing in a Convertible Note with a \$2.5mm cap. Their Series 5 raise in 2015 held a post-money valuation of \$27mm. In 2019, a private sale of shares indicates that the current valuation for the company may be considerably higher. Golden Seeds member enthusiasm for the company remains solid - Little Passports has recently closed on a \$1.5 million Convertible Note with a \$110 million cap which will convert into the next priced round at a 20% discount. To date, Golden Seeds investors, including the Fund, have invested \$2.7 million in the company.

Amy Norman, CEO of Little Passports will provide an overview on the company's exciting progress and plans for the future.

Nalu Bio – Open funding round

Nalu Bio is a science and data-driven ingredient company whose mission is to harness novel processes to bring high-quality natural compounds to market for consumer health and wellbeing. The company's mission is to learn from nature, and deliver through chemistry, creating a new category of cannabinoids and cognitive wellness ingredients which will offer great therapeutic promise for the treatment of pain, opioid addiction, and mental health issues.

The company has developed a proprietary cannabinoid chemical synthesis platform that will set a new industry standard for pure, consistent, and quality cannabinoids, because it eliminates both the impurities (no THC, no chemicals, no pesticides) and the high capital investment costs of hemp extraction and biosynthesis. This unique, scalable platform has the ability to keep pace with the anticipated \$20B CBD market and opens the path for drug development. Nalu Bio's business model is a B2B ingredient business to retailers near-term and a drug development business longer-term.

Golden Seeds was introduced to Nalu Bio in July 2020, during which time the company was raising a \$1.5 million Series Seed round with a \$8.5 million pre-money valuation led by L37 Capital. Golden Seeds members invested \$216,000 in the Series Seed. The company announced the successful close of the Series Seed round in January 2021, which will be used to further the development, perfection and validation of its chemistry platform and CBD output.

Caitlyn Krebs, CEO and a co-founder of Nalu Bio, is an entrepreneur with 20 years of health care experience, and will join us to discuss the CBD market, progress the company has made, plans for the coming year, and a current fundraising round.

Nanodropper - No open funding round.

Nanodropper is a universal eye drop bottle adaptor that reduces oversized droplets, removes financial barriers-to-care, and increases access to expensive eye drop medications. The simple and intuitive device has the potential to save billions of dollars in medication waste, one drop at a time.

By developing a patented, FDA approved sterile class I medical device that is used as an aftermarket adaptor, the company estimates that Nanodropper will extend the life of a prescription bottle of medication by 3-4 times, ensuring necessary treatment without interruption and reducing pharmaceutical costs per patient.

The company is currently in US clinical trials which are scheduled for completion in mid to late 2021 and is working on a third clinical trial in India which will help to open international markets.

Golden Seeds was introduced to Nanodropper in 2019 through our Silicon Valley chapter. Earlier this year, members invested \$184,000 in a \$1 million Series Seed round, with a \$6 million pre-money valuation. The round was overcommitted.

Mackenzie Andrews, the Chief Commercialization Officer, a device design engineer with a focus on technology commercialization, will talk about their strategy to build revenue, starting with a direct to clinic model and expanding into other channels. Jennifer Steger, Nanodropper's Chief Scientific Officer who leads the grant writing and clinical trial activity will also join us.

NopSec – open funding round

NopSec helps organizations to make better decisions to reduce IT security risk. Their SaaS approach to vulnerability risk management offers an intelligent solution to dramatically reduce the turnaround time between identification of critical vulnerabilities and remediation.

NopSec's flagship software, Unified VRM (Vulnerability Risk Management) system leverages vulnerability data from third party scanners, company specific asset data, threat intelligence, social media and other sources to separate truly critical vulnerabilities from the noise, allowing companies to prioritize remediation of the most critical vulnerabilities saving time, money and preventing the costliest security breaches.

Golden Seeds was first introduced to NopSec in April 2020. Members and the Golden Seeds Fund invested a total of \$272,500 in the company's Convertible Note offering with a \$10 million cap which will convert at a 20% discount in the next priced round.

Lisa Xu, CEO and Founder, has 2 decades of relevant experience, and has advised Fortune 500 enterprises on data security, privacy and technology risk management, and led many diverse teams at Ally Financial (GMAC), KPMG, and Blue Cross Blue Shield.

NX Prenatal –no open funding round

NX Prenatal is developing diagnostic assays for adverse pregnancy conditions such as preterm birth. It employs the proprietary NeXosome® platform, which enables advanced isolation and enrichment of exosome and microvesicle particles from bodily fluids for non-invasive biomarker evaluation. The company is currently planning the US launch of the NeXosome Preterm Birth Risk Assay, which detects a new library of biomarkers for prenatal risk assessment as early as 10 weeks gestation. This technology may provide physicians an ideal opportunity to intervene in a timely manner with protocols for at-risk pregnancies in an attempt to reduce the likelihood of a preterm birth or minimize the complications that can arise for both the child and the mother. This test is designed to help identify which asymptomatic pregnancies may result in the ~60% of 500,000 annual preterm births in the US that occur without warning.

In 2021, the company has expanded patent issuances for its exosome-based liquid biopsy tests for the early identification of pregnant mothers at elevated risk for spontaneous preterm birth in both the US and Europe. They have announced sponsorship and collaboration for an upcoming clinical study to identify pregnant patients with PAS. The company is executing well on their NIH study, and expect to have an internal read of data in June 2021 which may allow them to move to certification and commercialization. With clinical validation, they would envision an opportunity for the company's platform to provide multiple revenue generating product lines, each of which could be of interest to potential acquirers.

Golden Seeds was first introduced to the company in 2015, with members making their first investment in the Series A round, with a pre-money valuation of \$3.5 million, in early 2016. A Convertible Note in 2020 with a \$10 million cap was followed by a \$5 million Series A-3 round led by Solas BioVentures with pre-money valuation of \$16.5mm. To date, Golden Seeds members have, on a direct basis, invested \$655,000 to continue to support the company in clinical data production.

Brian Brohman, Co-Founder and Co-CEO of NX Prenatal, was previously the founding CFO of biotech startups Aptamera, Bradmer Pharmaceuticals, and NX PharmaGen, and will update the members on NX Prenatal's progress and plans for 2021.

Oculogica. Funding round planned in Fall 2021.

Oculogica's proprietary, patented technology transforms the way concussion is diagnosed. Founded by a neurosurgeon and research scientist, and a winner of the prestigious Luis Villalobos Award for Innovation, Oculogica has developed the first FDA authorized baseline free, technology to aid in diagnosis of concussion, also known as mild traumatic brain injury (mTBI). Oculogica is also conducting research with world-class medical institutions to bring personalized medicine to concussion diagnosis and treatment, with the goal of improving outcomes for the millions of people who annually suffer TBI and concussion.

Using ocular motility and other domains of brain function, the EyeBOX device helps physicians to determine the presence of concussion. Oculogica's device is the only concussion diagnosis technology based on published research on cranial nerve function and their relation to eye movements. Because Oculogica's technology is based on function, rather than the patient's "will", its proprietary approach does not require baseline testing, and eliminates subjectivity in a diagnosis.

Golden Seeds was first introduced to Oculogica in 2015, leading the company's Series Seed B round with a pre-money valuation of \$12.8mm. Members, through an LLC, and the Golden Seeds Funds, have continued to invest in the company through each of the follow-on rounds, and have invested more than \$2.7mm to date. In their most recent round in January 2020, Oculogica closed an \$8mm Series A round with a \$26mm pre-money valuation which was led by Titletown Tech, a venture fund led by the Green Bay Packers and Microsoft. Looking forward, the company anticipates a Series B raise in the Fall.

Dr. Rosina Samadani, CEO of Oculogica, will discuss progress the company has made over the past year, changes necessitated by the pandemic, and will update members on the expansion of the launch.

OnBoard Dynamics – Open funding round.

Onboard Dynamics has developed and built a proprietary mobile, self-powered, natural gas compressor, GoFlo, and other related products, which can supply fleets with Compressed Natural Gas (CNG) from the existing low-pressure natural gas grid infrastructure. In addition, their novel compressor technology enables natural gas utilities to perform critical pipeline maintenance in their efforts to address methane leakage.

Founded in 2013, Onboard Dynamics is helping lead the clean fuel revolution. Their mobile platform enables fleet managers and others in the industry to lower their fuel costs, reduce carbon emission profiles and provide critical backup capability by simplifying the compression of natural gas. Whether it's in the field, or at the fleet yard, the GoFlo mobile compressor can accept any low-pressure natural gas or a renewable natural gas source and compress it for use as a cost-effective, clean fuel for vehicles or means of transport into the marketplace.

The company will be launching a new product in May 2021 (the GoVAC™) to solve an urgent pain point for customers that perform pipeline maintenance and repair operations. And, in 2021, were excited to announce receipt of the first issued patent for their core technology.

Golden Seeds was first introduced to OnBoard Dynamics in 2018. Members have invested a total of \$480,000 in a \$2.5mm Convertible Note. The Note carries a \$6 mm cap, and 20% discount. The company has \$180,000 remaining on the Note and plans a final close for 2Q 2021.

As an essential business, while having modified the daily workflow to protect the team, Onboard Dynamics operations remained open throughout 2020, enabling them to ensure that customers have not faced disruptions. Rita Hansen, CEO at OnBoard Dynamics, will discuss progress the company has made over the past year, update members on the new market opportunity evolving with the GoVAC™, and highlight their role in leading the transition from traditional energy fuels to the next generation energy fuels.

Open Road – No open funding round

Open Road Integrated Media is a prestige content brand delivering digital experiences that entertain and inform readers around the world; their network of digital properties produce compelling stories that keep audiences engaged across devices and around the world. By unlocking the potential of a digitally connected audience, the company is producing scalable sales that deliver multi-year recurring revenue, content discoverability and proprietary technology tools that have become a SAAS service for partners.

The company holds the rights to approximately 10,000 e-books from more than 2,000 contemporary authors, and provides outsourced digital sales support for other publishers, under a program called Ignition, which covers an additional 20,000 titles. Open Road has more-than 1 million newsletter subscribers making 10 million impressions per month, and traffic of more than 1.4 million unique users driving more than 3 million page-views monthly. With 38 publishers contributing their powerful content, they can satisfy almost any reading need. There are more than 17mm books in the market, increasing by 1.3M new books annually. With bookstores closing, readers have shifted towards buying books online. Open Road Integrated Media saw 34% growth in 2020, a trend which has continued into 1Q 2021.

Golden Seeds was first introduced to Open Road in 2011, with both the Fund and Angels investing a total of \$1,000,000 in the Series B offering with a \$15 million pre-money. Both the Fund and individual angels have continued to support the company, having invested a total of nearly \$2.6 million, including the most recent round, a Convertible Note with a \$60mm cap.

Mary McAveney, CMO and CRO at Open Road, will speak to our members about the successful path the company has paved since our first investment.

OtoNexus. No open funding round

OtoNexus is developing the world's first medical device to provide objective diagnostic data to instantly and accurately diagnose middle ear infections (Otitis Media) in children and adults. A simple and elegant solution, the device applies a well-known medical technology, ultrasound, in a completely novel way to achieve a key advance in differentiating when and when not to

prescribe antibiotics. One-use-per-patient tips create a recurring revenue stream. The device will provide data in seconds and will be easy to use by physicians or non-physician personnel (NPs, PAs). Definitive, objective data identifying both the presence and the type of fluid behind the eardrum will lead to better outcomes and significantly reduced healthcare costs. With 6 patents issued, the company continues a US and international patent strategy to strengthen their intellectual property portfolio, as well as expansion of current filings in addition to registered trademarks for the company, product, and technology features.

Golden Seeds was first introduced to OtoNexus in 2015, with members investing in the company's Series A round with a pre-money valuation of \$3 million. The company later opened a Convertible Note which converted into the company's Series B with a pre-money valuation of \$16.3 million. Members have continued to support the company with investment in a second Note which later converted into recently closed Series C round, raising \$10 million with a pre-money valuation of \$32.5 million. To date, Golden Seeds members have invested \$1.4 million through GS OtoNexus LLC.

Caitlin Cameron, CEO of OtoNexus, and Gina Kelly, the company's chief product and marketing officer, whose combined 50+ years of experience in life sciences, biotech, technology, healthcare, marketing and management will update members on recent developments and the path towards commercialization.

Physician 360. No open funding round.

Physician 360™ (P360) is the next generation of minute clinic. Their mission is to reimagine the practice of urgent. P360 transforms community pharmacies into health clinics by empowering them with access to on-demand telehealth consults, rapid tests, and tools to diagnose and treat time-sensitive medical conditions like Strep, Flu, UTI, ear infection and COVID-19.

The company is creating value by increasing access to cost-effective, convenient, and diagnostically accurate care, especially in marginalized communities like rural America. There is a community pharmacy within a few miles of over 90% of Americans. By partnering with community pharmacies, P360 eliminates the need for patients to visit doctor offices, urgent cares, or ERs, saving not only time, but also money. Value is also created for the pharmacies, who view the addition of the P360 products and services as a source of additional store traffic and standard retail margins not only on the P360 test kits but also on the treatment prescriptions and OTC purchases, as well as incidental purchases.

Through their model, Physician 360™ has transformed over 1,000 independent pharmacies into urgent care centers and in 2020, achieved 200% year-over year growth for the second year in a row. They are striving to continue to grow their network and become the largest network of cost-effective, convenient, and diagnostically accurate healthcare centers in the country.

Golden Seeds members were first introduced to Physician 360 in mid-2020 through our Atlanta chapter. Members have invested \$157,500 in a \$1.5 mm Convertible Note, which will convert into a priced round at a 20% discount.

Founded by two Emergency Medicine doctors whose vision is to create the largest network of affordable care clinics in the country, Angela Fusaro, MD, MBA (CEO) and Robert Lapporte, MD (Chief Medical Officer) have been leading the company since 2018. Together they have 30+ collective years of clinical experience and are regarded as thought leaders in creative care delivery with expertise in healthcare operations. Angela, who will be updating our members, is a

board-certified EM physician, recent Assistant Professor at Emory University School of Medicine, and her expertise on telehealth and remote diagnostics has been featured in Forbes, The New York Times, HuffPost, The BBC and The Atlanta Business Chronicle.

Pomp & Whimsy - No open funding round

Pomp & Whimsy is the first super premium craft spirit designed by women, owned by women, marketed exclusively at women. The product formula has been developed through 3 rounds of market research and informed by 10+ years of insight derived from working extensively with the target audience in spirits and other industries. It is the first Gin Cordial to be created and marketed in the US. Low ABV, all natural, low sugar. 2020 highlights include annual revenue growth of 100% versus 2019, with Q1 2021 sales up 166% compared to the same quarter in 2020. While the global pandemic impacted hospitality and on-premise spirit sales, premiumization trends and increased at home consumption resulted in an increase of 43% in retail and off premise sales for the year.

Golden Seeds was first introduced to Pomp & Whimsy in February 2020. With a first close in 2020, and a second in 2021, members invested a total of \$205,000 in a Convertible Note which in March 2021 converted into a \$1.55 million Series Seed round. With a \$2.35 mm pre-money valuation, this round was led by El Dorado Partners.

Dr Nicola Nice, CEO of Pomp and Whimsy, is a trained sociologist and brand strategist-turned spirits producer. She has made a career advising Fortune 500 companies on international branding and consumer insights. Nicola has expertise in the national spirits sector through her work with clients including DIAGEO, Campari and Bacardi USA brands. She is on a mission to revolutionize the spirits industry for women, starting with Pomp and Whimsy.

Roar - Open funding round

ROAR, doing business as Performlive, is a live streaming marketplace for Creators and small businesses to build a following and monetize their talent, service, or products. In December 2020, faced with continued Covid impact, the founders moved to rebrand as Performlive to capitalize on the massive opportunity in live streaming. Performlive, which launched in Beta on April 4, delivers live streaming, commerce and augmented reality, all in one easy-to-use platform.

Targeting SMBs and Influencers who currently rely on one-way selling with recorded video or other video solutions without Commerce (think YouTube, Zoom, QVC), PerformLive offers the opportunity to engage and transact with audiences in real-time via one platform. Just as ROAR made it simple to create augmented content, Performlive makes live commerce and selling simple. A first patent for Performlive is being filed with the USPTO on May 10th.

In 2020, Roar raised a \$815,000 out of \$2 million Seed round with an \$8 million pre-money valuation, led by Golden Seeds. Golden Seeds member LLC and the Golden Seeds Venture Fund invested a total of \$302,500 in the round. After launching the first release of Performlive, management reinitiated fundraising efforts to complete the Seed round, with an expected close in May 2021.

Oksana Sokolovsky, CEO and co-founder, is a 3X Entrepreneur and has experience building and scaling global disruptive technology start-ups, including one that had a significant exit. Her

co-founder and CTO, Rohit Mahajan, was her partner in two exits and together with Oksana, created technology products while at Morgan Stanley and Deutsche Bank across data, regulatory, security, devops, and digital transformation domains.

Sara Happ – Open funding round

Sara Happ was founded on the idea that the lip industry is empirically broken. They have disrupted the lip care segment by identifying key ingredients and chemistry to produce innovative, well-formulated lip treatment products, including exfoliants, moisturizers, masks, and other first-to-market solutions for lip care.

The company, known as "The Lip Expert", is a developer, manufacturer and distributor of their lip treatment products which are sold through multiple channels of distribution including independent retail stores, retail chains, e-commerce, television, direct to consumer, and international retailers.

The global lip care products market was \$2.1B in 2019 and is anticipated to reach \$2.6B by 2025, the fastest growing category of skin care within the prestige beauty market. Since peaking in 2017, sales of makeup have slowed as many women have embraced a more natural appearance with an increased emphasis on skin care. Sales of skin-care products, though, have been on the uptick for the last three years, and in recent weeks, sales of skin-care products surpassed makeup sales for the first time ever.

Golden Seeds was first introduced to Sara Happ in 2018, and in 2020, members invested \$165,000 in the company's Convertible Note, with a \$6mm cap, which will convert into the Series A at a 20% discount to the Series A pricing.

Sara Happ, CEO, will speak with Golden Seeds members about how they were impacted over the past year, changes to distribution channels, the current market for skin care and specifically the lip care segment, and the outlook for the company and the industry.

Shareablee – No open funding round

Shareablee empowers brands to drive success by measuring social activity across platforms including Facebook, Instagram, Twitter and YouTube. Founded on a proprietary data taxonomy and monitoring more than 1M global companies and 9M+ influencers, Shareablee has been the leading authority on audience intelligence, competitive benchmarking and actionable insights since 2013.

With comprehensive monitoring in more than 55 countries, Shareablee is the world's largest system of social performance data for brands and agencies who want to understand the impact of their cross-platform campaigns.

Golden Seeds was first introduced to Shareablee in 2013, when members invested in its seed round. In 2014 members invested in the Series A with a pre-money valuation of \$12mm. Members have continued to participate in follow on rounds, including the 2019 Series A-2 with a pre-money valuation of \$32mm, and have invested a total of \$612,000 since the first investment.

Tania Yuki, CEO at Shareablee, will speak to Golden Seeds members about MarketEdge, the company's new offering, will discuss 2020 results and forecasts for the coming year.

Sports Innovation Lab – Open funding round

Sports Innovation Lab is the leading provider of sports market research and fan intelligence. The company provides market intelligence and data to decision-makers in sports, media, and entertainment. Customers use their data and information to stay on top of rapidly evolving trends, compare vendors, find partners, develop business, and conduct competitive intelligence. In addition, the company has spent several years helping customers with understanding their fan base. Now they are developing a dynamic insights engine that will provide a comprehensive profile of fans – including what they do, watch, and buy. This rich data will allow Sports Innovation Lab customers to make more informed decisions related to sponsorships, promotions, content, and other investments.

Golden Seeds members invested \$125,000 in a convertible note round in 2019, which will convert into the next equity financing at a 20% discount. The company is opening a new round and will discuss details with Golden Seeds members.

Angela Ruggiero is the co-founder and CEO of Sports Innovation Lab. Angela is a member of the 2015 Hockey Hall of Fame, a 4-time Olympian in ice hockey, winning a Gold Medal in 1998, Silver Medal in 2002 and 2010, and a Bronze Medal in 2006. Angela has also served on the US Olympic Committee and the International Olympic Committee Executive Board.

Angela Ruggiero will give an overview of Sport Innovation and discuss the exciting plans the company has for 2021.

Tempo Automation – No funding round

Tempo Automation is the world's fastest electronics manufacturer for prototyping and low-volume production of PCB assemblies. By developing and deploying proprietary factory automation software in its San Francisco-based smart factory, Tempo's industry-leading speed, precision, and start-to-finish transparency enable agile hardware development. Customers are able to plan and execute product development and launch with levels of confidence and certainty not previously possible.

Tempo Automation was first introduced to Golden Seeds in 2014 through our Silicon Valley office. A diligence team led by members including Joy Weiss, who later became CEO of Tempo and who we are thrilled to have speaking with our members today, were impressed with the team and our members, along with several Silicon Valley Angel and VC groups, invested in a SAFE with a \$5 million cap in early 2015. This SAFE converted into the \$1.5 million Series Seed financing later in 2015 at a \$7.5 million pre-money valuation. In 2017, the company raised a \$35 million Series B round, co-led by Industry Ventures Direct and Lux Ventures at a \$65 million pre-money valuation, and in 2019 participated in the company's \$40 million Series C financing based on a \$150 million fully diluted pre-money valuation led by Point72 Ventures. Since our first investment in 2015, Golden Seeds members have invested nearly \$2.5 million in Tempo, and have been excited to watch the growth of the company since our first investment.

Joy Weiss played a critical role in both in bringing this opportunity to Golden Seeds investors, serving on its Board, and now in role as CEO at Tempo, has continued to scale, automate and

optimize the technology, enhance the customer experience and improve operational performance.

Terecircuits - No Open Funding Round

Terecircuits has developed a unique, patent-protected material/technique that will facilitate the manipulation and rapid production of micro-electronics. This technique offers the potential to be 100x or faster than existing technology for manufacturing and is applicable for a broad range of micro-electronic manufacturing applications, however the initial target market is micro-LED manufacturing for electronics manufacturers and contract suppliers. With increasing consumer demand for high performance electronics, this market has no existing production manufacturing solution, and is poised to be a differentiator in the highly competitive panel TV, phone, and virtual reality viewing markets.

The company closed out 2020 having met or exceeded the deliverables they set for themselves early in the year. In addition to closing the Seed round, Terecircuits was awarded a \$256k NSF/SBIR Phase I Grant. They received industry recognition from two of the most followed MicroLED analysts, and two highly visible awards in 2020 startup competitions. Significant progress was made in the labs, and with new engagements.

Golden Seeds members first invested in Terecircuits in 2019 in a convertible note round with a \$4 million cap. In 2021, the company raised a second Note for \$1million in 2021 with an \$8 million cap which was oversubscribed. Both will convert into the priced round at a 20% discount. To date, members have invested \$460,000 in the company.

Wayne Rickard, CEO of Terecircuits will speak with members about the company's progress and plans for the future. Wayne has 25+ years' experience in bringing tech products to market and has held executive positions in similar B2B industries with long sales cycles, as well as previous startup experience through IPO.

Work Truck Solutions – No funding round.

Work Truck Solutions has developed and implemented an efficient and streamlined process to help dealers manage their commercial inventory and connect with their business buyers, reducing buyer pain points throughout the transaction process, while increasing profits for the commercial operation. Their commercial vehicle marketing platform has automated and simplified a decentralized and manual process for selling work trucks to the end customer. Work Truck Solutions provides a unique marketing platform and lead generation tool designed for the work truck industry. The company serves OEMs, body and equipment manufacturers, distributors and installers, and commercial vehicle dealers from all major brands across the United States, helping commercial vehicle dealers display and advertise their commercial vehicles online.

Through Work Truck's powerful marketing platform, dealers can display and advertise commercial vehicles online, creating a national marketplace focused on the commercial vehicle buyer, and helping them to search for vehicles that meet their specific needs. Their innovative solutions help dealers manage their commercial inventory and connect quickly with their business buyers.

The commercial automotive industry continues to be highly focused on digital, on-line, integrated, and efficiency solutions such as Work Truck Solutions, and the company is seeing increased interest from dealers, dealer groups (enterprise), and OEM corporate entities.

Golden Seeds was first introduced to Work Truck Solutions in 2016, with members investing over \$1mm in a Series B round led by Autotech with a post-money valuation of \$17.5mm. Members have continued to support the company, investing an additional \$500,000 in the Series B-1, with a post-money valuation of \$24.4mm. With a cash runway which extends into 2022, the company has no current funding round.

Kathryn Schifferle, CEO of Work Truck Solutions, will update members on actions the company has taken over the past year, and plans for the future.

Zenflow - No funding round

Zenflow was founded in 2014 by a team of Stanford University Biodesign Fellows working in collaboration with top global urologists. After witnessing patients' frustration with existing treatment options, the founders made it their mission to find a better solution to a largely unmet clinical need. Zenflow's goal is to develop a safer, less invasive, and more effective treatment. Because of the prevalence of benign prostatic hyperplasia (BPH or enlarged prostate), the space has grown from negligible in 2014 to a rapidly growing revenue run rate of ~\$500 million. The clinical need identified by Zenflow was real, and any new treatment that improves upon the effectiveness or invasiveness of the standard of care can expect fast market uptake.

The Spring® System is an office-based therapy that permanently relieves urinary obstruction related to BPH. This condition causes frequent and urgent urination that affects almost all men at some point in life. Current treatments fail to address the clinical need for millions of men.

The Spring® System is a small super elastic implant deployed through a flexible catheter in a simple and atraumatic procedure under direct visualization. As is often the case in medtech, optimizing the product has taken a few more iteration cycles than expected, but clinical data so far shows strong evidence that the device will be more effective, less invasive, safer, and easier to use than the current market leaders. Zenflow's goal of delivering a better treatment for millions of BPH patients is well within reach. Positive clinical data has continued to roll in. Patients in the trials have responded well to the procedure. The pivotal IDE has been submitted to the FDA, with a response anticipated in 2Q 2021. This will be a significant step to a commercial launch in the US.

Golden Seeds was first introduced to Zenflow in 2015, with members having first invested in a SAFE which converted into the company's Series A in 2017 at a \$20mm pre-money valuation. In the month of April, the company raised \$24 million in the Series B with a post money valuation of \$80 million. In total, members have invested \$1,166,000 through Golden Seeds Zenflow LLC.

Nick Damiano, CEO and Shreya Mehta, CTO will discuss the enormous milestones the company has achieved in the past 12 months, including a summary of Zenflow's clinical studies, and plans for the future.

